. Normal Mendelian segregation of progeny from breeding Igf2 and p53 heterozygous males and females by post-natal day 10. On a 129J strain, the progeny from Igf2 +m/-p females x p53 +/males and p53 +/females x Igf2 +m/-p males conformed to the expected Mendelian ratios. The progeny from a 129B6F1 cross also conformed to the expected Mendelian frequencies (3df). Whilst Igf2 +m/-p , p53 +/female x p53 +/male progeny conformed to the expected Mendelian segregation, although there was a trend towards significance (n=44, p=NS,   = 10.091) and it may be that the low numbers were confounding the analysis. Upper value -observed, middle valueexpected, lower value -  value. Except right-hand column where middle value -p value. A. Reduced litter size were derived from Igf2 +m/-p , p53 +/females (note Igf2 +m/-p denoted Igf2 +/for clarity). Significantly fewer progeny were obtained from mating of Igf2 +m/-p , p53 +/females with Igf2 +m/-p , p53 +/males (***p< 0.0001, 1-way ANOVA, mean of 64 litters) and Igf2 +m/-p , p53 +/females with WT males (**p < 0.01, mean of 25 litters) than from Igf2 +m/-p , p53 +/males with WT females (mean of 45 litters). B. Male (top, solid blue bars, total = 40) and female (bottom, solid red bars, total = 49) progeny from Igf2 +m/-p , p53 +/females mated with p53 +/males segregated according to the expected Mendelian distribution (gray, unfilled bars). The reduction of male offspring was independent of genotype and appeared significant (P < 0.05,  2 -test) compared to the expected numbers derived from all previous breeding from 129 mice. C. Uterine horns (upper panels) were removed from pregnant females at E9.5 and representative implantation sites shown (middle panels). In Igf2 +m/-p , p53 +/mothers, the maternal deciduas appeared abnormal, that was also evident in a small proportion of p53 +/mothers (arrows). Implantation sites from Igf2 +m/-p mothers appeared normal.
(Lower panel) Haematoxylin and eosin sections showed blood-filled implantation sites in Igf2 +m/-p , p53 +/mothers (right). Scale bar -1mm. D. Igf2 +m/-p , p53 +/females had significantly more haemorrhagic implantation sites (11/14) compared to p53 +/females (3/6) and Igf2 +m/-p females (0/16). (*P < 0.05, *** P < 0.0001, Fisher's exact test). There was no significant difference (p=0.826, one-way ANOVA) in the mean litter sizes between Igf2 -m/+p , p53 +/females mated with Igf2m/+p , p53 +/males (n=4 litters, mean litter size = 4.500 ± 0.500), Igf2 +m/-p , p53 +/females mated with Igf2 -m/+p , p53 +/males (n=7 litters, mean litter size = 4.000 ± 0.617), Igf2 +m/-p , p53 +/females mated with Igf2 +m/-p , p53 +/males (n=3 litters, mean litter size = 3.667 ± 0.333) and Igf2 -m/+p , p53 +/females mated with Igf2 +m/-p , p53 +/males (n=10 litters, mean litter size = 4.700 ± 0.817).
Figure S3.
Normal gross morphology but reduced growth in 129 Igf2 +m/-p female embryos. A. 129 Igf2 +m/-p females did not exhibit gross morphological abnormalities during development. Upper panel -WT embryo at E9.5 (n=7 examined) and E14.5-15.5 (n=1 examined). Lower panel -Igf2 +m/-p females at E9.5 (n=4 examined) and E14.5-15.5 (n=1 examined). B. & C. Reduced embryonic growth of mice that lack the paternal allele of Igf2 was independent of p53 and embryo sex (blue-males, red-females). Significant weight differences were matched in the embryo, placenta, liver, heart and brains (including brains weight normalised to body weight) of mice with intact Igf2 paternal allele (WT and p53 +/-) compared to mice functionally null for Igf2 (Igf2 +m/-p and Igf2 +m/-p , p53 +/-, p<0.0001, 1-way ANOVA, Tukey's multiple comparison).
Figure S4.
Survival of p53 WT or p53 homozygous null mice to 18 months was independent of Igf2 allelic dose and mouse strain. A, Top -There was no significant difference in survival of 129 p53 WT mice (p=NS, Log Rank test) with loss of Igf2 (Igf2 -p , n=31) compared to mice mono-allelic for Igf2 (Igf2 +p , n=20 or H19 +m , n=2). Middle -Gain of Igf2 function through disruption of H19 (H19 -m , n=15) did not alter survival of B6 p53 WT mice (p=NS, Log Rank test) compared to mice mono-allelic for Igf2 (H19 +m , n=22). Bottom -Loss of Igf2 (Igf2 -p , n=5) or gain of Igf2 (H19 -m , n=5) did not significantly alter survival of F2 hybrid p53 WT mice compared to mice mono-allelic for Igf2 (Igf2 +p , n=7 or H19 +m , n=6, p=NS, Log Rank test). B, Top -There was no significant difference in survival of 129 p53 -/mice with loss of Igf2 (Igf2 -p , n=31) or gain of Igf2 (H19 -m , n=2) compared to mice monoallelic for Igf2 (Igf2 +p , n=10 or H19 +m , n=3, p=NS, Log Rank test). Middle -Gain of Igf2 (H19 -m , n=15) did not alter survival of B6 p53 -/mice (p=NS, Log Rank test) compared to mice mono-allelic for Igf2 (H19 +m , n=22). Bottom -Loss of Igf2 (Igf2 -p , n=3) or gain of Igf2 (H19 -m , n=1) did not significantly alter survival of F2 hybrid p53 -/mice compared to mice mono-allelic for Igf2 (Igf2 +p , n=22 or H19 +m , n=3, p=NS, Log Rank test). NBnote low numbers in F2 analysis. Note abbreviations; Igf2 +p = Igf2 -m/+p and Igf2 +/+ . Igf2 -p = Igf2 +m/-p and Igf2 -/-. H19 +m = H19 +m/-p and H19 +/+ . H19 -m = H19 -m/+p and H19 -/-.
Figure S5.
Representative immunohistochemical labelling and classification of tumours using DAB substrate (brown) and haematoxylin (blue). All images x40 objective. Left column -lymphoma; positive for CD3 (T cell lymphoma), CD45R (B cell lymphoma) or both (mixed). Negative for cytokeratin, desmin and vimentin. Middle column (hepatocellular carcinoma) -positive for cytokeratin, vimentin positive = stromal cells, negative for CD3/CD45R and desmin. Right column (sarcoma)negative for CD3/CD45R and cytokeratin, positive for desmin and vimentin (stromal cells). Table - tumour histio-type assembled by genotype; classified by Histopathologist (FP) blinded to genotype. Number in brackets = males.
Genotype
Tumour type No. of tumours
H19 -m , p53 +/-(B6) Lymphoma Hepatocellular carcinoma Carcinoma (GI) Sarcoma 3(1) 1(1) 4(3) 2(0) Figure S6 . Sarcomas from p53 +/mice with bi-allelic Igf2 expressed higher Igf2 mRNA levels comparable to embryonic levels of expression. Igf2 and H19 mRNA expression normalised to 100,000 copies of β-actin. A. Embryos null for Igf2 paternal allele had a significantly lower Igf2 mRNA expression (Igf2 +m/-p , n=5) compared to WT (Igf2 +/+ , n=4, *p<0.05) and embryos bi-allelic for Igf2 (H19 -m/+p , n=3, ***p<0.0001). WT embryos had a significantly lower expression compared to embryos bi-allelic for Igf2. B. There was no significant differences in H19 mRNA expression between embryos null for Igf2 (Igf2 +m/-p , n=4) compared to WT (Igf2 +m/+p , n=4). Mice with bi-allelic Igf2 expression (H19 -m/+p , n=2) had significantly lower H19 mRNA expression compared to mice null and WT for Igf2. C. Igf2 mRNA expression was significantly different in the heart (n=2) compared to muscle (n=4), small intestine (n=3), liver (n=2) and thymus (n=3). There was no significant difference between other tissues. D. H19 mRNA expression was significantly different in the muscle (n=3) compared to small intestine (n=3), liver (n=2), thymus (n=4,) and heart (n=4). There was no significant difference between other tissues. E. Igf2 +p equals Igf2 -m/+p and Igf2 +/+ . Igf2 -p equals Igf2 +m/-p and Igf2 -m/-p . H19 +m = H19 +m/-p and H19 +m/+p . H19 -m = H19 -m/+p and H19 -m/-p . Black circles -male. Gray circles -female. Igf2 allelic dose did not affect Igf2 expression in lymphomas (Igf2 -p n=1, Igf2 +p /H19 +m n=16, H19 -m n=3) or carcinomas (Igf2 -p n=4, Igf2 +p /H19 +m n=7, H19 -m n=4). Loss of paternal Igf2 did not significantly alter Igf2 mRNA expression in sarcomas (Igf2 -p n=2) relative to Igf2 +p /H19 +m (n=2), implicating maternal allele expression (loss of imprinting). There was a significant increase in Igf2 mRNA expression in sarcomas with bi-allelic Igf2 expression (n=2) compared to monoallelic Igf2 tumors (Igf2 +p , p<0.05) and mice null for Igf2 (Igf2 -p , p<0.001). F. There was no significant difference in H19 mRNA expression dependent on Igf2 allelic dose in lymphomas (Igf2 -p n=2, Igf2 +p /H19 +m n=14, H19 -m n=1), carcinomas (Igf2 -p n=4, Igf2 +p /H19 +m n=6, H19 -m n=3) or sarcomas (Igf2 -p n=3, Igf2 +p /H19 +m n=2, H19 -m n=2). All 1-way ANOVA, Tukey's multiple comparison; ***p<0.0001, **p<0.001, *p<0.01.
Figure S7.
Igf2 expression did not correlate with either p53 or Mdm2 protein levels or localisation in solid tumours. A. There was no correlation between Igf2 mRNA level and nuclear p53 levels (above, n=13, p=NS, r = -0.43), or total p53 levels (below, n=13, p=NS, r = 0.32), B. Nuclear Mdm2 levels (above, n=13, p=NS, r = -0.002) and total Mdm2 levels (below, n=13, p=NS, r = 0.06, Spearman's) also did not correlate with Igf2 mRNA expression. (NS=not significant).
Figure S8.
Proliferation and apoptosis did not correlate with Igf2 mRNA expression in carcinomas and sarcomas p53 +/tumours. A. Mean percentage proliferating cells did not correlate with Igf2 expression levels (n=10, r = 0.13, p=NS). B -Whilst there was no correlation between mean percentage apoptotic cells and Igf2 expression (n=10, r = -0.59, p=NS) this was approaching significance (p=0.074, Spearman's).
Figure S9.
Igf2 allelic dose did not alter the frequency of ER-α positive solid tumours in p53 +/mice. A. There was no significant difference in the proportion of ER-α positive p53 +/tumours in Igf2 -p (n=1 male and 2 females) and ER-α negative tumours (n=3 males and 4 females) relative to Igf2 WT ER-α positive p53 +/tumours (n=4 males and 3 females) and ER-α negative tumours (n=2 males and 1 female, p=NS, Fisher's exact). There was no significant difference in the proportion of ER-α positive p53 +/tumours with bi-allelic Igf2 expression H19 -m (n=1 male and 1 female) and ER-α negative tumours (n=1 male and 1 female) relative to Igf2 WT p53 +/tumours (p=NS, Fisher's exact test).
